M. Phelps

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Mitchell Phelps, M. A. Phelps, M A Phelps, Mitchell A Phelps, Mitch A Phelps, Mitchell A. Phelps, Mitch A. Phelps, Mitch Phelps
Publication record
231 papers · 6,599 citations · H-index 39

PAPERS

Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).
20230 citationsauthor #9
Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice
20235 citationsauthor #22
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
202311 citationsauthor #9
Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma
20235 citationsauthor #7
Author Correction: Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice
20231 citationsauthor #22
Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab
202327 citationsauthor #2
Maternal-fetal biodisposition of buprenorphine and its metabolites in opioid dependent pregnant individuals
20230 citationsauthor #5
The effect of maternal body mass index on optimal dosing of aspirin for preeclampsia prevention
20230 citationsauthor #10
Pharmacokinetics and tolerability of multiple‐day oral dosing of mycophenolate mofetil in healthy horses
20232 citationsauthor #8
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia
20239 citationsauthor #11
Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.
20233 citationsauthor #7
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer
20235 citationsauthor #16
An Exploratory Analysis on the Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Received BCMA CAR-T Therapy in the Cartitude-1 Study
20230 citationsauthor #18
609 Nitric oxide dependent improved relapse free survival to ipilimumab therapy in melanoma patients
20220 citationsauthor #7
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
20223 citationsauthor #12
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
202234 citationsauthor #21
DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo.
202275 citationsauthor #9
Noncompartmental pharmacokinetics of three intravenous mycophenolate mofetil concentrations in healthy Standardbred mares.
20222 citationsauthor #7
Discovery of Anticancer Agents of Diverse Natural Origin.
2022112 citationsauthor #13
Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1
20220 citationsauthor #19
Abstract 1060: Introducing a novel DHODH inhibitor with superior in vivo activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
20220 citationsauthor #16
Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)
20220 citationsauthor #16
Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant
20220 citationsauthor #4
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
202210 citationsauthor #7
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
202117 citationsauthor #7
Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing
20215 citationsauthor #9
The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer
20218 citationsauthor #19
Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics
202146 citationsauthor #9
Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans
202116 citationsauthor #17
Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks
202111 citationsauthor #11
A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy
20214 citationsauthor #5
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
202119 citationsauthor #8
Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.
202157 citationsauthor #19
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
202126 citationsauthor #24
Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
20207 citationsauthor #7
Replication Study: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs
20207 citationsauthor #3
Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
202024 citationsauthor #14
Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant
20201 citationsauthor #9
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats
20202 citationsauthor #19
Pharmacological Prevention of Neonatal Opioid Withdrawal in a Pregnant Guinea Pig Model
20205 citationsauthor #12
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer
202027 citationsauthor #5
Phase I study of AR-42 and decitabine in acute myeloid leukemia
202017 citationsauthor #12
Abstract 6118: A primary mouse model of AML as a new way to screen novel therapeutics and treatment combinations
20200 citationsauthor #9
The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer
202038 citationsauthor #4
Author response: Replication Study: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs
20200 citationsauthor #3
Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
20204 citationsauthor #8
Abstract A32: The SUV39H1-H3K9me3 pathway represses cytotoxic T lymphocyte effector expression to confer colon carcinoma immune escape
20200 citationsauthor #14
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
20202 citationsauthor #7
PAGANZ 2019 Abstracts
20190 citationsauthor #4
Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al.
20197 citationsauthor #3
The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research.
2019181 citationsauthor #101
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion
201950 citationsauthor #14
Molecular Carcinogenesis
201910 citationsauthor #9
ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL
20191 citationsauthor #9
Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies
201912 citationsauthor #2
Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice
20197 citationsauthor #5
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173)
20190 citationsauthor #10
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in CLL mouse model.
201937 citationsauthor #13
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
201930 citationsauthor #4
Optimising time samples for determining area under the curve of pharmacokinetic data using non‐compartmental analysis
201910 citationsauthor #4
A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients
201812 citationsauthor #6
Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies.
20184 citationsauthor #16
Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42
20182 citationsauthor #11
Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?
201826 citationsauthor #3
Drug quantification in metastatic brain tumors in patients receiving bendamustine as a radiosensitizer for stereotactic radiotherapy.
20180 citationsauthor #19
CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
201831 citationsauthor #12
Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant
201814 citationsauthor #14
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration
20182 citationsauthor #16
PRMT5 as a druggable target for glioblastoma therapy
201893 citationsauthor #11
Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry
20176 citationsauthor #7
G-CSF improves safety when you start the day after autologous transplant in multiple myeloma
20176 citationsauthor #12
Novel clone selection technique reveals heterogeneity among HEK293T cells engineered to produce therapeutic extracellular vesicles
20170 citationsauthor #8
Abstract 141: CD44 positive and sorafenib resistant hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
20170 citationsauthor #8
OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia
20171 citationsauthor #17
Rituximab immunotherapy: it's getting personal.
20171 citationsauthor #1
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells
2017475 citationsauthor #13
Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest
20172 citationsauthor #9
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant
201735 citationsauthor #8
Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading
20170 citationsauthor #3
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
201755 citationsauthor #11
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study
2017127 citationsauthor #18
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma
201725 citationsauthor #10
Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.
20177 citationsauthor #5
Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery
201779 citationsauthor #11
Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading
2017115 citationsauthor #3
Associations of High‐Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial
201731 citationsauthor #16
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration
201773 citationsauthor #16
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma
201717 citationsauthor #15
Pharmacokinetic and pharmacodynamic correlations of flavopiridol in the treatment of chronic lymphocytic leukemia.
20160 citationsauthor #1
In vitro immunotoxicity assessment of culture-derived extracellular vesicles in human monocytes
201619 citationsauthor #4
CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia
20160 citationsauthor #17
G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma
20166 citationsauthor #9
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
201680 citationsauthor #8
Abstract 2068: Engineering of hairpin loop enhances the loading of endogenously expressed pre-miRNA into extracellular vesicles
20161 citationsauthor #7
A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.
20163 citationsauthor #7
Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease
20162 citationsauthor #11
Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs
201633 citationsauthor #1
Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules
20163 citationsauthor #6
Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents
201616 citationsauthor #14
NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
20167 citationsauthor #24

TIMELINE

2002 74 citations

2003 62 citations

2004 298 citations

2005 180 citations

2006 50 citations

2007 432 citations

2008 133 citations

2009 504 citations

2010 274 citations

2011 951 citations

2012 292 citations

2013 163 citations

2014 255 citations

2015 257 citations

2016 455 citations

2017 1,055 citations

2018 184 citations

2019 345 citations

2020 134 citations

2021 209 citations

2022 236 citations

2023 68 citations

Unknown 0 citations

M. Phelps

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT